Hot Healthcare Equipment Companies For 2014

When investors think of non-Hodgkin's lymphoma stocks, big names like Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) come to mind. Both GILD and CELG are making prolific progress in the war on NHL, and both are fine, well-positioned companies. It's little Infinity Pharmaceuticals Inc. (NASDAQ:INFI) that may end up making the proverbial quantum leap in the non-Hodgkin's lymphoma stocks arena, however, and better still, it's INFI shares that may well end up doling out a much bigger reward than Gilead or Celgene could to newcomers.

The non-Hodgkin's lymphoma is worth about $6 billion per year now, and is projected to be worth more than $8 billion by 2019. That's why so many companies are working on treatments. Not all of them are making rapid or effective progress though. In fact, Celgene Corporation announced a couple of days ago that its Revlimid trial (as a treatment for B-cell lymphomatic leukemia) was being discontinued due it ineffectiveness. The drug and the company are still a player in the NHL world, but the drug's failure is an example of how blood-related cancers are not easy diseases to target.

Top 10 Penny Stocks To Buy For 2015: Unisys Corporation (UIS)

Unisys Corporation provides information technology (IT) services, software, and technology that solve mission-critical problems for clients worldwide. It operates in two segments, Services and Technology. The Services segment provides outsourcing services, including management of customers� data centers, computer servers, and end-user computing environments, as well as specific business processes; systems integration and consulting services, such as assessing the security and cost effectiveness of clients� IT systems and enabling them to design, integrate, and modernize mission-critical applications; infrastructure services consisting of design, warranty, and support services for its customers� IT infrastructure, such as networks, desktops, servers, and mobile and wireless devices; and maintenance services. The Technology segment designs and develops servers and related products consisting of enterprise-class servers, which comprise the ClearPath family of servers and t he ES7000 family of Intel-based servers, as well as operating system software and middleware; and provides data center, infrastructure management, and cloud computing offerings for clients to virtualize and automate their data-center environments. The company serves public sector; financial services; and other commercial markets comprising communications and transportation. Unisys Corporation markets its products and services primarily through direct sales force, as well as through distributors and alliance partners. Unisys Corporation was founded in 1886 and is headquartered in Blue Bell, Pennsylvania.

Advisors' Opinion:

• [By Alex Planes]

  Originally built by Eckert and Mauchly under their own brand, UNIVAC proved so costly and time-consuming to develop that the duo sold their business to Remington-Rand -- which still operates in the computing industry today as Unisys (NYSE: UIS  ) -- before completing the project. UNIVAC was designed from the ground up for business use rather than scientific calculation, and represented the first real digital threat to IBM's (NYSE: IBM  ) punched-card tabulators, which had been the Census Bureau's preferred number-crunching tools for decades. However, their astronomically high cost -- $750,000 for the eight-ton machine and another $185,000 for the high-speed printer -- kept UNIVAC from becoming a big-business hit, even after it nailed the results of President Dwight Eisenhower's landslide 1952 election victory with only 1% of the vote recorded. That wasn't for lack of trying on Remington Rand's part:

• [By Monica Gerson]

  Unisys (NYSE: UIS) is estimated to post its Q3 earnings at $0.40 per share on revenue of $854.13 million.

  Harley-Davidson (NYSE: HOG) is expected to report its Q3 earnings at $0.73 per share on revenue of $1.17 billion.

Hot Healthcare Equipment Companies For 2014: Hornbeck Offshore Services(HOS)

Hornbeck Offshore Services, Inc., through its subsidiaries, operates offshore supply vessels (OSVs), multi-purpose support vessels, and a shore-base to provide logistics support and specialty services to the offshore oil and gas exploration and production industry primarily in the United States and Gulf of Mexico. It operates in two segments, Upstream and Downstream. The Upstream segment owns and operates fleets of the U.S.-flagged OSVs that support deepwater and ultra-deepwater exploration, development, production, construction, installation, maintenance, repair, and enhanced oil recovery requirements of the oil and gas industry. This segment also owns conventional OSVs, work class ROVs, and a shore-base facility located in Port Fourchon, Louisiana. In addition, it provides vessel management services for other vessels owners, which include crewing, daily operational management, and maintenance activities. The Downstream segment owns and operates a fleet of ocean-going tug s and tank barges that transport petroleum products, primarily in the northeastern United States, the Gulf of Mexico, the Great Lakes, and Puerto Rico. These tugs and tank barges provide coastwise transportation of refined and bunker grade petroleum products, as well as offer other services, including the support of deepwater well testing and other applications for refining, marketing, and trading companies. As of December 31, 2009, Hornbeck Offshore Services owned and operated a fleet of 47 new generation OSVs, and 9 double-hulled barges and 10 ocean-going tugs. The company was founded in 1997 and is headquartered in Covington, Louisiana.

Advisors' Opinion:

• [By Ben Levisohn]

  “There will be blood,” one analyst noted this morning about Hornbeck Offshore Services (HOS) –but his observation could apply to just about the entire offshore-services sector, as Atwood Oceanics (ATW), Diamond Offshore (DO) and Ensco (ESV) tumble.

• [By Traders Reserve]

  For investors who want a piece of this developing trend, Transocean and Seadrill are two of the bigger players in this arena. Other offshore drillers/rig operators are Noble (NE) and Ensco (ESV). Companies that provide services to offshore drillers and benefit from increases in exploration and drilling activity are Gulfmark Offshore (GLF), Hornbeck (HOS), Seacor (CKH) and Tidewater (TDW).

Hot Healthcare Equipment Companies For 2014: Array BioPharma Inc.(ARRY)

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases in North America, Europe, and the Asia Pacific. Its programs under development include ARRY-520, a kinesin spindle protein inhibitor in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie-2 dual inhibitor in Phase 1 clinical trial for patients with myelodysplastic syndrome; ARRY-380, a HER2 inhibitor in Phase 1 clinical trial for breast cancer; ARRY-797, a p38 inhibitor in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist in Phase 1 clinical trial for allergic inflammation. The company?s partnered drugs in clinical development comprise Selumetinib and AZD8330 MEK inhibitors for cancer in Phase 2 trial; MEK162 and MEK300 MEK inhibitors for cancer in Phase 2 trial; Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 trial; ARRY-543, a HER2/EGFR inhibitor in Phase 2 trial for solid tumors; and LY2603618, a ChK-1 inhibitor in Phase 2 trial for cancer. Its partnered drugs in clinical development also include AMG 151, a glucokinase activator in Phase 1b trial for Type 2 diabetes; GDC-0068, a AKT inhibitor in Phase 1b trial for cancer; VTX-2337, a toll-like receptor in Phase 1b trial for cancer; VTX-1463, a toll-like receptor in Phase 1b trial for allergy; ARRY-382, a cFMS inhibitor in Phase 1 trial for cancer; and ARRY-575 and GDC-0425, which are ChK-1 inhibitors in Phase 1 trial for cancer. The company has collaborations with Amgen, Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Genentech, Inc.; Novartis International Pharmaceutical Ltd.; InterMune, Inc.; Eli Lilly and Company; and VentiRx Pharmaceuticals, Inc for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.

Advisors' Opinion:

• [By Dan Carroll]

  Array's phase 2 study pays off big
  It's tough to find a stock anywhere on the market that had as good a week as Array BioPharma (NASDAQ: ARRY  ) . Shares of the biotech picked up nearly 17.8% on the week, part of a 63.5% gain year-to-date. The company's developmental drug to treat persistent allergic asthma, ARRY-502, hit the right marks in improving patient lung function in phase 2 trial results. Even better for investors, Array CEO said several other health companies have shown interest to help the company in development of ARRY-502.

• [By John Udovich]

  Biotech and the cancer treatment segment of the biotech market has been a hot area for some time with important cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps�Array BioPharma (NASDAQ: ARRY), Cancer Genetics Inc (NASDAQ: CGIX), EXACT Sciences Corporation (NASDAQ: EXAS) and�MetaStat Inc (OTCMKTS: MTST) all producing a steady flow of important news�for investors this week or in recent weeks. Consider the following:

• [By Sean Williams]

  Array BioPharma (NASDAQ: ARRY  ) presented some particularly intriguing findings with its MEK inhibitor, selumetinib, which it has licensed out to AstraZeneca�to treat uveal melanoma (cancer of the eye). Historically this is a very difficult to treat disease, but initial studies of selumetinib more than doubled the time it took for the disease to progress compared to the current standard of treatment, temozolomide. In trials, selumetinib delivered 15.9 weeks without disease progression, an overall response rate of 50%, and major tumor shrinkage exhibited in 15% of patients. For temozolomide, steady disease was only established for a median of seven weeks with no tumor shrinkage present.�

Hot Healthcare Equipment Companies For 2014: Micrel Incorporated(MCRL)

Micrel Incorporated, doing business as Micrel Semiconductor, designs, develops, manufactures, and markets high-performance analog power, mixed-signal, and digital integrated circuits (ICs) primarily in North America, Europe, and Asia. It offers power management products, including cloud, single-board, and enterprise servers; network switches and routers; storage area networks; and wireless base stations for the networking and communications infrastructure markets. The company also provides power management standard products for industrial, consumer, defense, and automotive electronics markets. In addition, it manufactures custom analog and mixed-signal circuits; and provides wafer foundry services for the customers who produce electronic systems for communications, consumer, and military applications. Further, the company offers general linear parts; power analog circuits; high speed physical media devices and interface ICs; and Ethernet products, which comprise physical l ayer transceivers, media access controllers, switches, and system-on-chip devices. Additionally, it provides radio frequency (RF) data communications products, including QwikRadio family of RF receivers and transmitters, which include garage door openers, lighting and fan controls, automotive keyless entry, and remote controls; and RadioWire transceivers for applications, such as remote metering, security systems, and factory automation. The company?s products address a range of end markets, including cellular handsets, portable computing, enterprise and home networking, wide area and metropolitan area networks, digital televisions, and industrial equipment. Micrel Incorporated sells its products through a network of independent sales representatives, independent distributors, and stocking representative firms, as well as through a direct sales staff. The company was founded in 1978 and is based in San Jose, California.

Advisors' Opinion:

• [By Evan Niu, CFA]

  What: Shares of Micrel (NASDAQ: MCRL  ) jumped temporarily this morning, up by as much as 10% before giving back nearly all of those gains, following first-quarter earnings.

Hot Healthcare Equipment Companies For 2014: Precision Drilling Corp (PDS)

Precision Drilling Corporation (Precision) is a provider of contract drilling and completion and production services primarily to oil and natural gas exploration and production companies in Canada and the United States. The Company operates in two segments: Contract Drilling Services, and Completion and Production Services. In Canada, the Contract Drilling Services segment includes land drilling services, directional drilling services, procurement and distribution of oilfield supplies and the manufacture and refurbishment of drilling and service rig equipment, and the Completion and Production Services segment includes service rigs for well completion and workover services, snubbing services, camp and catering services, wastewater treatment services and the rental of oilfield surface equipment, tubulars, well control equipment and wellsite accommodations. Advisors' Opinion:

• [By Lee Jackson]

  Precision Drilling Corp. (NYSE: PDS) is Canada’s leading oilfield services firm, which provides contract drilling, well servicing and strategic support services to its customers. The company was formed as a private drilling contractor in the early 1950s and has grown on the back of fleet expansion and acquisitions, most notably the $2 billion purchase of Grey Wolf in 2008. The company pays investors a 2.1% dividend. The Jefferies price objective goes from $11 to $13. The consensus stands at $12.78. The stock closed Friday at $10.39.